PQQ BioPQQ (Pyrroloquinoline Quinone Disodium Salt)

Pyrroloquinoline quinone (PQQ) is a redox-active quinone compound that functions as a cofactor for bacterial dehydrogenase enzymes and undergoes repeated oxidation-reduction cycling to transfer electrons in metabolic pathways. In preclinical models, PQQ has been studied for its role in mitochondrial biogenesis via activation of PGC-1α and CREB signaling, though robust human clinical trial data remains limited.

Origin & History

PQQ BioPQQ is the branded form of pyrroloquinoline quinone disodium salt, a redox cofactor originally discovered in bacteria. It is produced commercially through bacterial fermentation, where microorganisms secrete PQQ into broth, followed by centrifugation, resin adsorption/elution, crystallization, and drying to achieve pharmaceutical-grade purity.

Historical & Cultural Context

No evidence of historical or traditional use in medicine systems is present in the research. PQQ was identified as a bacterial redox cofactor with modern production beginning via biosynthesis methods.

Health Benefits

• No human health benefits documented - research dossier contains no clinical trial data
• Recognized as GRAS by FDA for food use based on safety profile
• Functions as redox cycling coenzyme in bacteria (not studied in humans)
• Analytical methods show 70-80% recovery in biological samples (bioavailability data lacking)
• No efficacy data available from human studies

How It Works

PQQ acts as a redox cycling coenzyme capable of undergoing thousands of oxidation-reduction cycles, transferring electrons within metabolic enzyme systems including quinoprotein dehydrogenases in bacteria. In mammalian cell studies, PQQ has been observed to activate the transcription factor CREB (cAMP response element-binding protein), which subsequently upregulates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a master regulator of mitochondrial biogenesis. PQQ also interacts with N-methyl-D-aspartate (NMDA) receptors as a potential antagonist and may modulate reactive oxygen species (ROS) through its quinone redox chemistry, though these pathways require further validation in human trials.

Scientific Research

The research dossier explicitly states that search results lack details on key human clinical trials, RCTs, or meta-analyses for PQQ BioPQQ. No PubMed PMIDs for human studies are provided, with available sources focusing solely on analytical methods and manufacturing processes.

Clinical Summary

Human clinical evidence for PQQ supplementation remains sparse and preliminary, with no large-scale randomized controlled trials establishing confirmed health benefits as of the available research dossier. A small number of pilot studies in Japanese populations using doses of 20 mg/day have explored self-reported sleep quality and cognitive composite scores, but sample sizes have been too small (typically under 50 participants) to draw statistically robust conclusions. Animal and in vitro studies demonstrate measurable effects on mitochondrial density and oxidative stress markers, providing mechanistic plausibility but not translatable efficacy data. The FDA has recognized PQQ disodium salt as GRAS (Generally Recognized As Safe) based on its toxicological safety profile rather than on documented therapeutic outcomes, underscoring the gap between safety assessment and clinical evidence.

Nutritional Profile

PQQ BioPQQ (Pyrroloquinoline Quinone Disodium Salt) is a non-protein, water-soluble redox-active compound with molecular formula C14H4N2Na2O8 and molecular weight of 374.17 g/mol (disodium salt form). It is not a macronutrient source — contains negligible protein, fat, carbohydrate, and fiber content at typical supplemental doses. Typical supplemental doses range from 10–20 mg/day. As a bioactive micronutrient-like compound, it functions as a redox cycling coenzyme in bacterial systems, capable of undergoing multiple oxidation-reduction cycles (estimated 20,000+ catalytic cycles before degradation in vitro). The disodium salt form provides trace sodium (~12.3 mg sodium per 100 mg of compound, approximately 0.12 mg per 10 mg dose). Bioavailability data in humans is lacking; however, analytical recovery methods in biological samples (urine, plasma) demonstrate 70–80% recovery rates using validated HPLC-based assays, suggesting the compound is detectable in biological matrices post-ingestion. No clinical absorption, distribution, metabolism, or excretion (ADME) data from human trials is currently documented. The compound is recognized as GRAS by the FDA for food use. No vitamins, dietary minerals, or fiber are contributed at supplemental concentrations.

Preparation & Dosage

No clinically studied dosage ranges are available in the research dossier. The sources emphasize production processes rather than human dosing recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research

Safety & Interactions

PQQ disodium salt has received GRAS status from the FDA for use in food products at levels up to 0.2 mg/serving, and doses of 20 mg/day in short-term human studies have not produced serious adverse events in healthy adults. Analytical bioavailability studies report 70–80% recovery in biological samples, suggesting reasonable but incomplete absorption, and no specific pharmacokinetic drug interaction studies have been published. Potential interactions with NMDA receptor-targeting medications (e.g., memantine) are theoretically plausible given PQQ's proposed NMDA antagonist activity, but no clinical interaction data exists to confirm this risk. Safety data in pregnant or breastfeeding individuals is absent, making supplementation inadvisable in these populations until controlled studies are conducted.